4D Molecular Therapeutics, Inc. (FDMT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$14.97+1.84%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
4D Molecular Therapeutics is growing revenue fast, from $1,000 in 2024-Q4 to $85 million in 2025-Q4. The company beat earnings twice recently, showing improving financial performance. It has a strong cash position of about $514 million to fund development. The stable market and no recent stress support a recovery story.
The company is still loss-making with negative EPS expected through 2027. Revenue is forecast to decline sharply by 66% next year. Management is volatile with recent CEO and CFO changes. The biotech sector is risky and the company faces clinical and regulatory hurdles.
The stock trades about 23% below our fair value near $16. Analysts expect a 66% revenue decline next year, which we view as overly pessimistic. Our fair value assumes some recovery in financial performance.
Breaks if: cash falls below $300 million
Breaks if: EPS worsens or losses deepen beyond -$4 per share
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
FDMT represents a speculative growth investment. The current thesis state has weakened due to declining company momentum and increased volatility in management execution.
The market appears to price in a significant expectations gap, suggesting that investors anticipate strong future performance despite current challenges. Valuation is considered expensive compared to peers, which may not fully reflect the company's recent struggles.
Fundamentals are mixed, with management making progress on clinical trials but facing risks from potential guidance cuts and a weakening jobs report. The company remains loss-making, which adds to the uncertainty.
Key factors include management's ability to advance clinical trials successfully and the performance of sector bellwethers that could influence the overall healthcare market. Any negative guidance or economic downturn could further impact FDMT's outlook.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. Recent financial performance dropped from the top half to the bottom half of its industry. This change indicates that the reason to own FDMT has weakened. The market has not yet reacted to these weaker fundamentals, as the price is up 24% versus the S&P since the performance drop.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management is focused on improving financial performance, as evidenced by recent earnings beats.
Breaks if: annual revenue falls below $50 million
Management is focused on improving financial performance, as evidenced by recent earnings beats.
Over the next 1 to 3 years, FDMT's trajectory will depend on successful clinical developments and market conditions. Not investment advice.